Cardiovascular outcomes · Phase 3
REWIND: cardiovascular outcomes
What was tested?
Dulaglutide versus placebo in people with type 2 diabetes and cardiovascular disease or risk factors. ↗
Registered primary question: Time to the first cardiovascular death, nonfatal heart attack or nonfatal stroke. ↗
What the reviewed report found
Journal year 2019 · Article summary reviewed 2026-09-15
The primary cardiovascular composite occurred in 12.0% with dulaglutide versus 13.4% with placebo (hazard ratio 0.88; 95% CI 0.79–0.99). Gastrointestinal adverse events were more frequent with dulaglutide.↗
Keep in context: The reported median follow-up was 5.4 years. The composite result does not establish benefit for every component, and all-cause mortality did not differ significantly. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 9,901 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 50 Years; maximum not specified
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2019-10-08; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
REWIND: cardiovascular outcomes
- Design in the report
- A blinded randomized placebo-controlled trial followed participants for a median of 5.4 years.↗
- Participants in the report
- The trial enrolled 9,901 adults aged at least 50 with type 2 diabetes and cardiovascular disease or risk factors.↗
- Limitations
- The composite combines different outcomes and does not imply improvement in every component. All-cause mortality was not significantly different; these results do not establish effects in people without type 2 diabetes.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) ↗
Protocol identifier: 13438. Sponsor: Eli Lilly and Company.
Retrieved 2026-09-20; SHA-256 8d901c2f545dfc0ad1f156d5a598bb80149091277760af78f564e132b269baf4.
PMID 31189511
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 31189511. SHA-256 0e6795be99af1c93f3a3e2726fc8a17152661ca29e8dead110bff36feb856127.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 935add390b4c371ea1cc07cd33e4e8ced2482ff54ebdbca13b79c8f5e499402a.